A new definition for metabolic associated fatty liver disease: an international expert consensus statement.
By M. Eslam, P. Newsome, Q. Anstee, G. Targher, M. Gómez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, J. Dufour, J. Schattenberg, M. Arrese and 20 more. Journal of Hepatology, 2020
3,051 citations recorded by the source corpus.
The exclusion of other chronic liver diseases including "excess" alcohol intake has till now been necessary to establish a diagnosis of metabolic-dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, "positive criteria" to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis versus non-steatohepatitis. The group also suggests a set of criteria to define MAFLD associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/0610c5c5468983b28659f77fc0014ed151fb048a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Epidemiology
In Pathology and Forensic Medicine
Citations in the corpus
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023, neutral): “Indeed, there is a recognition now that there are overlapping biological processes that may contribute to both NAFLD and alcohol-associated/related liver disease (ALD).”
- The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease (2020, background): “to describe a cohort of patients with a liver disease that histologically mimicked alcoholic steatohepatitis in patients without a history of significant alcohol intake and has been in use [150] till recently [29].”